PO
Patient Reported Outcomes
Thursday, June 2, 2016: 6:15 PM-8:15 PM
Exhibit Hall
Gender Differences in Health Related Quality of Life in Multiple Sclerosis Patients with Increasing Disability
Allison LaRussa, BA, Brigham and Women's Hospital;
Alicia S Chua, M.S., Brigham and Women's Hospital;
Brian C Healy, PhD, Brigham and Women's Hospital;
Fiona Stuart, BA, Brigham and Women's Hospital;
Kaitlynne Leclaire, BA, Brigham and Women's Hospital;
Riley Bove, MD, Brigham and Women's Hospital;
Maria K Houtchens, MD, Brigham and Women's Hospital;
Sandra Cook, RN, Brigham and Women's Hospital;
Tanuja Chitnis, MD, Massachusetts General Hospital for Children;
Howard L Weiner, MD, Brigham and Women's Hospital;
Bonnie I Glanz, PhD, Brigham and Women's Hospital
Impact of Multiple Sclerosis Disease Type on Productivity in a Propensity-Matched Cohort of Narcoms Participants
Amber Salter, PhD, Washington University in St. Louis;
Nina Thomas, MPH, Genentech, Inc;
Gary Cutter, PhD, University of Alabama at Birmingham;
Tuula Tyry, PhD, Dignity Health, St. Joseph's Hospital and Medical Center;
Ruth Ann Marrie, MD, PhD, University of Manitoba;
Ashley Porter, PhD, Articulate Science
Autoinjector Ease-of-Use in Patients with Multiple Sclerosis Treated with Interferon ß-1a Subcutaneously: Preliminary Data from REDEFINE
Sibyl Wray, MD, Hope Neurology Multiple Sclerosis Center;
Barry A Singer, MD, The MS Center for Innovations in Care, Missouri Baptist Medical Center;
Brooke Hayward, SM, MBA, EMD Serono, Inc.;
Choon Cha, MD, EMD Serono, Inc.;
Michele Springer, BA, Caudex
MS Self™, an Educational Application for People with Multiple Sclerosis (MS): Patient Experience in Recording MS-Related Symptoms and Daily Activities
Cynthia B. Guerra, MBA, Acorda Therapeutics, Inc;
Brandy Northcutt, _, Acorda Therapeutics, Inc;
Richard Muser, _, Acorda Therapeutics, Inc;
Michael Russo, _, Acorda Therapeutics, Inc;
Joe McBride, _, Studio PMG;
Adrian L. Rabinowicz, MD, Acorda Therapeutics, Inc;
Eileen Rodriguez, CMP, Curry Rockefeller Group
A Phase IV Open-Label Study of Clinical Outcome Assessments to Facilitate Patient–HCP Interaction in MS: Study Design and Rationale
Donald Barone, DO, Rowan University;
Mark Gudesblatt, MD, South Shore Neurologic Associates;
Susan E Bennett, PT, DPT, EdD, NCS, MSCS, State University of New York at Buffalo;
Megan Weigel, DNP, ARNP-C, MSCN, Baptist Neurology Beaches Division;
Amy Perrin Ross, APN, MSN, CNRN, MSCN, Loyola University Chicago;
Brooke Hayward, SM, MBA, EMD Serono, Inc.;
Frederick Munschauer, MD, EMD Serono, Inc.;
Michele Springer, BA, Caudex
Conjoint Analysis of Preferred Features of a Hypothetical First Dose Observation Program Among Patients and Neurologists before Fingolimod Initiation in Multiple Sclerosis
Edward J. Fox, MD, PhD, Central Texas Neurology Consultants;
John Ko, Pharm.D, MS, Novartis Pharmaceuticals Corporation;
Paul Wicks, PhD, PatientsLikeMe Inc.;
Yujin Park, PharmD, University of Maryland School of Pharmacy;
Pronabesh DasMahapatra, MD, MPH, PatientsLikeMe Inc.;
Kathryn Kendall, MBA, PatientsLikeMe Inc.;
Walter Hong, MD, Novartis Pharmaceuticals Corporation;
Erik Burton, MD, Novartis Pharmaceuticals Corporation;
Kathleen Hawker, MD, Novartis Pharmaceuticals Corporation;
Irina Kosoy, BBA, Gfk;
Dimitri Liakhovitski, PhD, Gfk;
Vivian Herrera, DDS, MIA, MPH, Novartis Pharmaceuticals Corporation
Treatment Satisfaction Across Injectable, Infusion, and Oral Disease-Modifying Therapies for Multiple Sclerosis
Fiona Stuart, BA, Brigham and Women's Hospital;
Alicia S Chua, M.S., Brigham and Women's Hospital;
Allison LaRussa, BA, Brigham and Women's Hospital;
Kaitlynne Leclaire, BA, Brigham and Women's Hospital;
Sandra Cook, RN, Brigham and Women's Hospital;
Tanuja Chitnis, MD, Massachusetts General Hospital for Children;
Howard L Weiner, MD, Brigham and Women's Hospital;
Brian C Healy, PhD, Massachusetts General Hospital;
Bonnie I Glanz, PhD, Brigham and Women's Hospital;
Fiona Stuart, BA, Brigham and Women's Hospital
MS in US Minorities: Continuation of a Research Study Designed to Understand Educational Needs of Hispanic and African American Patients with MS
Gregory D Salinas, PhD, CE Outcomes, LLC;
Brandon Coleman, BS, CE Outcomes, LLC;
Eleana Hardy, BA, Biogen;
Jeffrey Smith, MS MBA, Biogen;
Leslie Meltzer, PhD, Biogen;
Terrie Livingston, PharmD, Biogen
Real-World Patient Retention and Satisfaction on Fingolimod Versus Platform Injectable Disease-Modifying Therapies in Early RRMS: Results from PREFERMS
Heidi Crayton, MD, MS Center of Greater Washington;
Brian Steingo, MD, Sunrise Medical Group;
DeRen Huang, MD, PhD, Neurology and Neuroscience Associates;
Xiangyi Meng, PhD, Novartis Pharmaceuticals Corporation;
Lesley Schofield, PhD, Novartis Pharmaceuticals Corporation;
Kristen Johnson, PhD, Novartis Pharmaceuticals Corporation;
Nadia Tenenbaum, MD, Novartis Pharmaceuticals Corporation;
* on behalf of the PREFERMS investigators, **please delete**, **please delete**;
Jeremy Bright, PhD, Oxford Pharmagenesis;
Terence Smith, PhD, Oxford Pharmagenesis
Development and Use of the iConquerMS Research Network for Patient-Centered Research
Hollie Schmidt, MS, Accelerated Cure Project for MS;
Robert N. McBurney, PhD, Accelerated Cure Project for MS;
Deborah Backus, PT, PhD, Shepherd Center;
Laura Kolaczkowski, BA, Accelerated Cure Project for MS;
Sara Loud, MSEE, MBA, Accelerated Cure Project for MS;
Revere P. Kinkel, MD, University of California San Diego
Treatment Patterns Associated with Relapsing-Remitting Multiple Sclerosis Patients on 1st-Line Injectable Disease Modifying Therapies
Jacqueline Nicholas, MD, MPH, Ohio Health;
John Ko, Pharm.D, MS, Novartis Pharmaceuticals Corporation;
Yujin Park, PharmD, University of Maryland School of Pharmacy;
Prakash Navaratnam, Rph, MPH, PhD, DataMed Solutions LLC.;
Howard Friedman, PhD, DataMed Solutions LLC.;
Frank Ernst, Pharm.D, MS, Indegene TTM;
Erik Burton, MD, Novartis Pharmaceuticals Corporation;
Walter Hong, MD, Novartis Pharmaceuticals Corporation;
Vivian Herrera, DDS, MIA, MPH, Novartis Pharmaceuticals Corporation;
Prakash Navaratnam, Rph, MPH, PhD, DataMed Solutions LLC.
Gastrointestinal Symptoms in Early Dimethyl Fumarate Therapy
John Foley, MD, Rocky Mountain MS Research Group;
Tamara Hoyt, MS, Rocky Mountain MS Research Group;
Cortnee Roman, NP, Rocky Mountain MS Research Group;
Angelene Christensen, BS, Rocky Mountain MS Research Group;
Ryan Metzger, PhD, Rocky Mountain MS Research Group;
Ryan Metzger, PhD, Rocky Mountain MS Research Group
The Effect of Comorbid Allergies on the Physical and Psychosocial Outcomes of Multiple Sclerosis Patients – a Th1/Th2 Paradigm of Autoimmune Disease
Joss Cohen, MD candidate, University at Buffalo Jacobs School of Medicine;
Katelyn S. Kavak, MS, New York State Multiple Sclerosis Consortium;
Caila B Vaughn, MPH, Jacobs MS Center of Treatment and Research;
Robert Zivadinov, MD, PhD, New York State Multiple Sclerosis Consortium;
Jessica F Robb, MD, University of Rochester Medical Center;
Burk Jubelt, MD, SUNY Upstate Medical University;
Lore Garten, MD, MS Center of Northeastern New York;
Ilya Kister, MD, New York State Multiple Sclerosis Consortium;
Lauren Krupp, MD, NYU Langone Medical Center;
Malcolm Gottesman, MD, Winthrop Comprehensive MS Care Center;
Barbara E. Teter, PhD, MPH, University at Buffalo;
Bianca Weinstock-Guttman, MD, New York State Multiple Sclerosis Consortium
Determining MS Relapses in Clinical Practice: How Do Clinicians Decide?
Kelsey Zorn, BA, Johns Hopkins Bloomberg School of Public Health;
Katherine J Kim, MPH, Evidera;
Louis S. Matza, PHD, Evidera;
Glenn Phillips, PhD, Biogen;
Kitty S. Chan, PHD, Johns Hopkins Bloomberg School of Public Health;
Sandra D. Cassard, ScD, Johns Hopkins School of Medicine;
Katherine C Smith, PhD, Johns Hopkins Bloomberg School of Public Health;
Ellen Mowry, MD, MCR, Johns Hopkins School of Medicine
Delayed-Release Dimethyl Fumarate in Relapsing Multiple Sclerosis after Suboptimal Response to Glatiramer Acetate: Respond 6-Month Interim Analysis
Kiren Kresa-Reahl, MD, Providence Multiple Sclerosis Center;
Pavle Repovic, MD, PhD, Swedish Neuroscience Institute;
Derrick S Robertson, MD, University of South Florida;
Macaulay Okwuokenye, DrPH, Biogen;
Leslie Meltzer, PhD, Biogen;
Jason Mendoza, PhD, Biogen;
Jim B Lewin, PharmD, Biogen
What Factors Influence Changes in MS Management? Comparing the Perspectives of Patients and Health Care Providers Using Nominal Group Technique
Andrew J Solomon, MD, University of Vermont College of Medicine;
Haiyan Qu, PhD, MHSA, University of Alabama, Birmingham;
Vicky Springmann, MSc, Public Health Ontario;
Carolina Ionete, MD, PhD, University of Massachusetts Memorial Medical Center;
Enrique Alvarez, MD, University of Colorado;
Lori Pbert, PhD, University of Massachusetts Memorial Medical Center;
Carolyn Griffin, RN, University of Massachusetts Medical School;
Brenda Tierman, RN, Shared Decision Making Resources;
Ashli Hopson, BA, Shared Decision Making Resources;
Christen Kutz, PA, PhD, Colorado Springs Neurological Associates;
Idanis Idanis Berriosmorales, MD, University of Massachusetts Memorial Medical Center;
Glenn Phillips, PhD, Biogen Idec Inc., Weston, MA, USA;
Nananda F Col, MD, MPH, MPP, FACP, Shared Decision Making Resources;
Nananda F Col, MD, MPH, MPP, FACP, Shared Decision Making Resources
Improvements in Patient-Reported Outcomes (PROs) with Teriflunomide: Results from the US Cohort of the Teri-PRO Phase 4 Study
Patricia K Coyle, MD, Stony Brook University;
Chris LaGanke, MD, North Central Neurology Associates;
Bhupendra Khatri, MD, The Regional MS Center, Center for Neurological Disorders, Wheaton Franciscan Health Care;
Keith R Edwards, MD, Multiple Sclerosis Center of Northeastern New York;
Steve Cavalier, MD, Genzyme, a Sanofi company;
Pascal Rufi, MD, Genzyme, a Sanofi company;
Sandrine Brette, MSc, Lincoln;
Miqun Robinson, MD, PhD, Sanofi;
Matt Mandel, MD, Genzyme, a Sanofi company;
Ralf Gold, MD, St. Josef-Hospital, Ruhr University Bochum
Factors Associated with Sexual Dysfunction in Patients with Multiple Sclerosis: An Exploratory Study
Samantha Domingo, Psy.D., Cleveland Clinic;
Lael A. Stone, M.D., Cleveland Clinic Foundation;
Shauna Clement, PA-C, Cleveland Clinic Foundation;
Nicolas Thompson, M.S., Cleveland Clinic Foundation;
Amy Sullivan, Psy.D., Cleveland Clinic;
Samantha Domingo, Psy.D., Cleveland Clinic;
Amy Sullivan, Psy.D., Cleveland Clinic
Patient-Reported Outcomes in Patients with Varying Clinical Disease Activity of Relapsing-Remitting Multiple Sclerosis in the DECIDE Study
Wanda Castro-Borrero, MD, Biogen;
Mariko Kita, MD, Virginia Mason Multiple Sclerosis Center;
Eva Havrdova, MD, PhD, Charles University in Prague;
Bhupendra Khatri, MD, The Regional MS Center, Center for Neurological Disorders, Wheaton Franciscan Health Care;
Keith R Edwards, MD, Multiple Sclerosis Center of Northeastern New York;
Bruce AC Cree, MD, PhD, University of California San Francisco;
Shulian Shang, PhD, Biogen;
Glenn Phillips, PhD, Biogen;
Ying Liu, PhD, Biogen
Case Report: Use of Fingolimod in an Hispanic MS Pediatric Patient
Eduardo R Estades, MD, San Juan MS Center;
Angel Chinea, MD, San Juan Multiple Sclerosis Center;
Yatzka G Hernandez Silvestrini, MD, San Juan MS Center;
Ivonne Vicente, MD, San Juan Multiple Sclerosis Center;
Cristina Rubi, BS, San Juan Multiple Sclerosis Center;
Eduardo R Estades, MD, San Juan MS Center;
Angel Chinea, MD, San Juan Multiple Sclerosis Center
